Raised $4.1B across disclosed rounds.[5]

SPAC / PIPE closed May 2021, led by Baillie Gifford.[1][8]

post-money valuation is not publicly disclosed.

Named investors include Viking Global Investors, Cascade Investment, Baillie Gifford, General Atlantic, Y Combinator, Senator Investment Group, T. Rowe Price Associates, Illumina, Putnam Investments, Counterpoint Global (Morgan Stanley Investment Management), ARK Investment Management, Bain Capital Public Equity, Berkshire Partners, Franklin Advisers, Casdin Capital, Felicis Ventures, OS Fund, Data Collective, iGlobe Partners, Vast Ventures, Allen & Company.[1][2][7][8][9]

Jason Kelly, Co-founder and CEO[1][9][10][11][12][16]

Reshma Shetty, Co-founder[1][9][10][11][12][16]

Barry Canton, Co-founder and CTO[1][9][10][11][12][16]

Tom Knight, Co-founder[1][9][10][11][12][16]

Austin Che, Co-founder[1][9][10][11][12][16]

Shyam Sankar, Chairman[5][16]

Zymergen · zymergen.com · Same buyer and same job: Ginkgo and Zymergen both sold cell/strain engineering services to industrial and pharma R&D organizations, and Ginkgo's talent pool draws heavily from Zymergen (67 hires).[5]

LabGenius · labgenius.com · Same buyer and same workflow: both sell high-throughput protein and strain engineering to biopharma R&D buyers, and Ginkgo's own enrichment data lists LabGenius as a direct competitor.[5]

Strella Biotechnology · strellabiotech.com · Listed as a direct competitor in Ginkgo's enrichment data, competing for the same industrial biotech R&D services buyer.[5]

The customer proof is company-sourced only. No independent source in this ledger confirms it.[9]

Ask for one referenceable production customer.

Not a recommendation. The first thing this ledger cannot answer.

Filled in the side panel for invited readers. This card carries sourced facts only.